GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alembic Pharmaceuticals Ltd

Alembic Pharma Q1 FY27 Consolidated Net Profit Rs. 173.07 Crores

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Aug 2026, 02:10 PM IST  ·  BSE ID: fb51dd23-a7df-418d-88ec-aa7f2f17f86d
View Original BSE Filing (PDF)
💡
In Simple Terms
Alembic Pharmaceuticals announced its quarterly financial results, showing its revenues and profits for the period.
🤖 AI Summary
  • Alembic Pharmaceuticals Board approved Q1 FY27 Consolidated and Standalone Unaudited Financial Results on August 4, 2026.
  • Consolidated Revenue from Operations for Q1 FY27 was Rs. 2,149.77 Crores.
  • Consolidated Profit for the Period after non-controlling interests reached Rs. 173.07 Crores.
  • Standalone Revenue from Operations for Q1 FY27 was Rs. 1,868.06 Crores.
  • Standalone Profit for the Period stood at Rs. 196.96 Crores.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations Q1 FY27
Rs. 2,149.77 Crores
25.66%
Consolidated Profit for the Period Q1 FY27
Rs. 173.07 Crores
12.10%
Standalone Revenue from Operations Q1 FY27
Rs. 1,868.06 Crores
25.02%
Standalone Profit for the Period Q1 FY27
Rs. 196.96 Crores
89.65%
Consolidated Basic & Diluted EPS Q1 FY27
Rs. 8.80
12.10%
Standalone Basic & Diluted EPS Q1 FY27
Rs. 10.02
89.94%
🏢 How This Affects the Company
📈
Business Impact
Consolidated Revenue from Operations increased to Rs. 2,149.77 Crores in Q1 FY27 from Rs. 1,710.72 Crores in Q1 FY26, indicating business growth.
💰
Financial Impact
Consolidated Profit for the Period increased to Rs. 173.07 Crores in Q1 FY27 from Rs. 154.38 Crores in Q1 FY26, impacting earnings.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as these results provide an update on the company's financial performance, specifically Consolidated Profit for the Period of Rs. 173.07 Crores.
🔍
Management Signal
The approval of the unaudited financial results signals management's adherence to regulatory disclosure requirements and reporting on company performance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q2 FY27 financial results — check for sustained revenue and profit growth.
Management commentary on segment performance for Q1 FY27.
Updates on any strategic initiatives or business development plans.
LOW RISK The filing reports routine quarterly financial results with an unqualified audit review.
💡 Investor Takeaway
Alembic Pharmaceuticals reported consolidated Revenue from Operations of Rs. 2,149.77 Crores in Q1 FY27, up from Rs. 1,710.72 Crores in Q1 FY26. Consolidated Profit for the Period was Rs. 173.07 Crores, increasing from Rs. 154.38 Crores in the prior year quarter.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Revenue from Operations increased to Rs. 2,149.77 Crores in Q1 FY27, up from Rs. 1,710.72 Crores in Q1 FY26.
  • Consolidated Profit for the Period grew to Rs. 173.07 Crores in Q1 FY27 from Rs. 154.38 Crores in Q1 FY26.

⚠️ Concerns

  • Consolidated Net Profit Margin declined to 8.05% in Q1 FY27 from 9.02% in Q1 FY26.
  • Standalone Net Profit Margin decreased to 10.54% in Q1 FY27 from 14.14% in Q4 FY26.
📅 Company Track Record
Alembic Pharmaceuticals previously informed BSE on July 24, 2026, about the Board meeting scheduled for August 4, 2026, to approve these Q1 FY27 Unaudited Financial Results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Alembic Pharmaceuticals' consolidated revenue in Q1 FY27?
Alembic Pharmaceuticals reported a consolidated Revenue from Operations of Rs. 2,149.77 Crores for the quarter ended 30th June, 2026.
What was Alembic Pharmaceuticals' consolidated net profit in Q1 FY27?
The consolidated Profit for the Period after non-controlling interests for Alembic Pharmaceuticals in Q1 FY27 was Rs. 173.07 Crores.
What was Alembic Pharmaceuticals' standalone revenue in Q1 FY27?
Alembic Pharmaceuticals' standalone Revenue from Operations for the quarter ended 30th June, 2026, was Rs. 1,868.06 Crores.
What was Alembic Pharmaceuticals' standalone net profit in Q1 FY27?
The standalone Profit for the Period for Alembic Pharmaceuticals in Q1 FY27 was Rs. 196.96 Crores.
What was the consolidated Earnings Per Share for Alembic Pharmaceuticals in Q1 FY27?
Alembic Pharmaceuticals reported consolidated Basic & Diluted Earnings per share of Rs. 8.80 for the quarter ended 30th June, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.